Open Orphan PLC New Contract Win (6533Z)
22 Septembre 2020 - 8:00AM
UK Regulatory
TIDMORPH
RNS Number : 6533Z
Open Orphan PLC
22 September 2020
22 September 2020
Open Orphan plc
("Open Orphan" or the "Company")
New Contract Win
Open Orphan plc (ORPH), a rapidly growing specialist CRO
pharmaceutical services company which is the world leader in the
testing of vaccines and antivirals using human challenge clinical
trials is pleased to announce Open Orphan's Paris subsidiary Venn
Life Sciences ("Venn") has secured an important new contract to
support a major European pharmaceutical company.
The Paris team of Venn will be assisting a prospective,
multicentre, longitudinal, non-interventional oncology study which
is expected to enrol over 750 subjects whereby Venn will handle all
data management, statistics and medical writing for the study.
This contract reinforces Venn's position as one of the leading
providers of data-management, statistics and medical writing
services to many of Europe's leading pharmaceutical and biotech
companies, a service the Company has a strong track record or
providing.
Cathal Friel, Executive Chairman of Open Orphan, said:
"Venn Life Sciences Holdings plc which is now part of Open
Orphan plc acquired Cardinal Systems in Paris in 2014. Cardinal had
a history dating back to 1996 of providing high-quality
data-management, statistics and randomisation services to many of
Europe's leading pharmaceutical companies in particular with a
focus in the French pharma and biotech sector. In the past year
since Open Orphan acquired Venn, we have substantially rationalised
and restructured the Paris based team who are now incentivised to
grow the business going forward with a strong focus on the original
Cardinal Systems' core skills in biometry including data
management, statistics, and medical writing. Since our acquisition
of hVIVO in January, our Venn team in Paris are also providing
biometry services to hVIVO as part of their challenge study
contracts and thereby improving the overall margin of challenge
study delivery. Previously, hVIVO outsourced required biometry
services to a third party.
This industry leading team in our Paris office has the knowledge
and track record which has allowed us to continue to grow the
business by winning large, long-term contracts such as the one we
have announced today. We look forward to delivering on the contract
and continuing to support large pharmaceutical companies as we
rapidly grow Open Orphan."
For further information please contact
Open Orphan plc +353 (0)1 644 0007
Cathal Friel, Executive Chairman
Arden Partners plc (Nominated Adviser and +44 (0)20 7614
Joint Broker) 5900
John Llewellyn-Lloyd / Benjamin Cryer /
Dan Gee-Summons
+44 (0) 20 7220
finnCap plc (Joint Broker) 500
Geoff Nash / James Thompson/ Richard Chambers
Davy (Euronext Growth Adviser and Joint
Broker) +353 (0)1 679 6363
Anthony Farrell
+44 (0)20 3757
Camarco (Financial PR) 4980
Tom Huddart / Hugo Liddy
Notes to Editors - Open Orphan:
Open Orphan is a rapidly growing niche CRO pharmaceutical
services company which is a world leader in the testing of vaccines
and antivirals through the use of human challenge clinical trials.
Conducted from Europe's only 24-bedroom quarantine clinic with
onsite virology providing individually isolated rooms and connected
to our specialist laboratory facility. hVIVO's challenge studies
require healthy volunteers to take part, volunteers are recruited
through FluCamp, learn more at www.FluCamp.com . The hVIVO facility
offers highly specialised virology and immunology laboratory
services to support pre-clinical and clinical respiratory drug,
antiviral, and vaccine discovery and development. Reliable
laboratory analysis underpinned by scientific expertise is
essential when processing and analysing clinical samples. Robust
quality processes support our team of scientists in the delivery of
submission ready data.
The Company has a leading portfolio of 8 viral challenge study
models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough and 1 COPD
viral challenge models. As announced in early March, Open Orphan is
rapidly advancing a number of Coronavirus challenge study models
and expects to be helping many COVID-19 vaccine development
companies to test their vaccines. No other company in the world has
such a portfolio, with only two competitors globally having 1
challenge study model each. hVIVO also works with companies in the
UK and Ireland to provide COVID-19 testing to staff to protect
staff and customers from a workplace COVID-19 outbreak through its
COVID Clear offering.
Open Orphan comprises of two commercial specialist CRO services
businesses, hVIVO and Venn Life Sciences and is also building out a
valuable data platform business. hVIVO has built up one of the
world's largest databases of infectious disease progression data
and we are populating our Open Orphan Health Data platform with
this historical hVIVO data. In our clinical trials going forward,
we are also planning to collect data on volunteer's via wearables
during clinical trials. Therefore, Open Orphan's data, which may
yield valuable digital biomarkers, could be one of the more
sought-after datasets by many of the large wearables /smart watch
wearables providers around the world. In June 2019, Open Orphan
acquired AIM-listed Venn Life Sciences Holdings plc in a reverse
take-over and in January 2020 it completed the merger with hVIVO
plc in January 2020. Venn is an integrated drug development
consultancy firm which offers CMC (chemistry, manufacturing and
controls), preclinical, Phase I & II clinical trials design and
execution. The merger with hVIVO created a European full pharma
services company broadening the Company's customer base and with
complementary specialist CRO services, widened the range of the
Company's service offerings.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTKKDBKBBKBNCB
(END) Dow Jones Newswires
September 22, 2020 02:00 ET (06:00 GMT)
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024